SRX's grand (and now perhaps only) competitor, BTG according to...

SRX's grand (and now perhaps only) competitor, BTG according to Jefferies as reported by Reuters are still into interventional medicine and TheraSpheres: no mention of liver cancer even tho BTG is known for its liver cancer beads and TheraSpheres, see below: like SRX, BTG has been oversold IMHO: must be an anti-biopharma flavor for the moment, or investors have got sick of liver cancer treatments with its high difficulty for trials, like SRX, BTG is excellent value, like Professor Chow do not like AMGN tho, Onyx did not meet the mark, see below:
Jefferies Group LLC Reaffirms Buy Rating for BTG plc (BTG)

Posted by Don Majors on May 19th, 2017
Jefferies Group LLC reiterated their buy rating on shares of BTG plc (LON:BTG) in a research report sent to investors on Tuesday morning. Jefferies Group LLC currently has a GBX 775 ($10.00) target price on the stock.
A number of other research analysts have also weighed in on the company. Investec reaffirmed a buy rating and set a GBX 720 ($9.29) price objective on shares of BTG plc in a report on Thursday, April 6th. Panmure Gordon reiterated a buy rating and set a GBX 737 ($9.51) target price on shares of BTG plc in a research report on Thursday, April 20th. Numis Securities Ltd reiterated a buy rating and set a GBX 900 ($11.62) target price on shares of BTG plc in a research report on Tuesday, April 25th. JPMorgan Chase & Co. reiterated a neutral rating and set a GBX 790 ($10.20) target price on shares of BTG plc in a research report on Tuesday, March 21st. Finally, Stifel Nicolaus reiterated a buy rating and set a GBX 725 ($9.36) target price on shares of BTG plc in a research report on Tuesday, April 4th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. BTG plc has an average rating of Buy and an average target price of GBX 763.78 ($9.86).
BTG plc (LON:BTG) opened at 646.00 on Tuesday. The stock’s market cap is GBX 2.51 billion. BTG plc has a 12 month low of GBX 528.36 and a 12 month high of GBX 739.50. The stock’s 50 day moving average price is GBX 653.83 and its 200-day moving average price is GBX 600.22.
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
BTG shares hit as medical product outlook disappoints
British healthcare group BTG (BTG.L) disappointed investors on Tuesday with a slower-than-expected forecast for growth in its interventional medicine business, sending the shares nearly 10 percent lower.
Despite reporting full-year sales that were slightly ahead of forecasts, helped by strong demand for DigiFab, an antidote for overdose of heart drug digoxin, prospects were weighed down by the cautious outlook for 2017/18, which analysts said put estimates at risk.
BTG - previously best known for drugs to treat overdoses and rattlesnake bites - has been reinventing itself in recent years by focusing on interventional medicine, in which image-guided devices are used to treat a range of diseases.
While established products in this division are selling well, growth has been slower for two newer products that are seen as pivotal for long-term success, Varithena for varicose veins and PneumRx for propping open diseased lungs.
For the current year, BTG said interventional medicine would deliver mid-to-high teens percentage sales growth, at constant exchange rates (CER), well below the 26 percent that analysts at Jefferies said they had been forecasting.
Adjusted operating profit in the year to end-March was up 13 percent at CER at 129.6 million pounds.
BTG shares, which have performed strongly this year on hopes for the company's shift to interventional medicine, were 9.5 lower at 653.5 pence by 1030 GMT. That is still up on the end-2016 level of 590p.
http://uk.reuters.com/article/uk-btg-results-idUKKCN18C0NA
https://sportsperspectives.com/2017...llc-reaffirms-buy-rating-for-btg-plc-btg.html